Farther Finance Advisors LLC Purchases 1,737 Shares of Viking Therapeutics, Inc. $VKTX

Farther Finance Advisors LLC boosted its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 571.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,041 shares of the biotechnology company’s stock after acquiring an additional 1,737 shares during the period. Farther Finance Advisors LLC’s holdings in Viking Therapeutics were worth $54,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Viking Therapeutics by 121.5% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 29,721 shares of the biotechnology company’s stock valued at $718,000 after purchasing an additional 16,302 shares during the last quarter. Wealth Management Associates Inc. acquired a new position in Viking Therapeutics in the first quarter valued at approximately $241,000. GAMMA Investing LLC boosted its stake in Viking Therapeutics by 9,209.9% in the first quarter. GAMMA Investing LLC now owns 24,392 shares of the biotechnology company’s stock valued at $589,000 after acquiring an additional 24,130 shares during the last quarter. Kingstone Capital Partners Texas LLC bought a new position in Viking Therapeutics in the second quarter valued at approximately $1,367,000. Finally, Wesbanco Bank Inc. grew its holdings in Viking Therapeutics by 118.5% during the 2nd quarter. Wesbanco Bank Inc. now owns 52,000 shares of the biotechnology company’s stock worth $1,378,000 after acquiring an additional 28,200 shares during the period. 76.03% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Citigroup increased their price target on Viking Therapeutics from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Raymond James Financial cut their target price on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating on the stock in a research note on Thursday, July 24th. HC Wainwright restated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a report on Monday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Saturday, September 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a research report on Monday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Viking Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $86.42.

Viking Therapeutics Stock Performance

NASDAQ:VKTX opened at $32.28 on Tuesday. The stock has a 50-day simple moving average of $29.28 and a 200 day simple moving average of $27.93. Viking Therapeutics, Inc. has a 52-week low of $18.92 and a 52-week high of $81.73. The company has a market cap of $3.63 billion, a PE ratio of -21.10 and a beta of 0.64.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). The company’s revenue was up NaN% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) earnings per share. On average, research analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.